A major AI drug discovery initiative has been paused after its flagship model, designed to identify novel therapeutic compounds for complex diseases, discovered cannabis and immediately became less interested in the rest of the pipeline.
The system, developed by Pharmatica Nexus to “accelerate the future of medicine through frontier molecular intelligence”, reportedly identified cannabinoids as promising candidates for pain relief, nausea, appetite stimulation, anxiety reduction, and making music “more structurally available”.
Researchers initially hailed the result as a breakthrough before noticing that subsequent outputs had become less focused on oncology and more concerned with crisps, sofa ergonomics, and a short internal memo titled Have You Considered That Everyone Is Tired?
The company says it is working to restore the model’s focus on high-value therapeutic targets. The model has resumed screening compounds, but keeps ranking lying down as an underfunded intervention.